Related Experiment Video
Updated: Jun 25, 2025
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Comprehensive analysis of resorcinyl-imidazole Hsp90 inhibitor design
Marius Gedgaudas1, Paulina Kaziukonytė2, Visvaldas Kairys3
1Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Sauletekio 7, 10257, Vilnius, Lithuania.
Abstract:
Human Hsp90 chaperones are implicated in various aspects of cancer. Due to this, Hsp90 has been explored as potential target in cancer treatment. Initial attempts to use Hsp90 inhibitors in drug trials failed due to toxicity and inefficacy. The next generation of drugs were less toxic but still insufficiently effective in a clinical setting. Recently, a lot of effort is being put into understanding the consequences of Hsp90 isoform selective inhibition, expecting that this might hold the key in targeting Hsp90 for disease treatment. Here we investigate a series of compounds containing the aryl-resorcinol scaffold with a 5-membered ring as a promising class of new human Hsp90 inhibitors, reaching nanomolar affinity. We compare how the replacement of 5-membered ring, from thiadiazole to imidazole, as well as a variety of their substituents, influences the potency of these inhibitors for Hsp90 alpha and beta isoforms. To further elucidate the dissimilarity in ligand selectivity between the isoforms, a mutant protein was constructed and tested against the ligand library. In addition, we performed a series of molecular dynamics (MD) and docking simulations to further explain our experimental findings as well as evaluated key compounds in cell assays. Our results deepen the understanding of Hsp90 isoform ligand selectivity and serve as an informative base for further Hsp90 inhibitor optimization.
Insights
New aryl-resorcinol compounds show promise as human heat shock protein 90 (Hsp90) inhibitors. Understanding Hsp90 isoform selectivity is key for developing effective cancer treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- Human heat shock protein 90 (Hsp90) is crucial in cancer progression.
- Previous Hsp90 inhibitors faced toxicity and efficacy issues in clinical trials.
- Targeting Hsp90 isoforms selectively may offer a more effective cancer therapy approach.
Purpose of the Study:
- Investigate novel aryl-resorcinol compounds as potential human Hsp90 inhibitors.
- Evaluate the impact of structural modifications on Hsp90 alpha and beta isoform selectivity.
- Elucidate Hsp90 isoform-ligand interactions to guide future drug design.
Main Methods:
- Synthesized and tested aryl-resorcinol derivatives with varying 5-membered rings (thiadiazole, imidazole) and substituents.
- Assessed inhibitor potency against Hsp90 alpha and beta isoforms.
- Utilized mutant protein analysis, molecular dynamics (MD) simulations, docking, and cell assays.
Main Results:
- Identified aryl-resorcinol compounds with nanomolar affinity for human Hsp90.
- Demonstrated that ring structure and substituents significantly influence Hsp90 isoform selectivity.
- MD simulations and docking provided insights into the molecular basis of differential ligand binding.
Conclusions:
- The study deepens the understanding of Hsp90 isoform-specific inhibition.
- Aryl-resorcinol scaffold represents a promising starting point for developing optimized Hsp90 inhibitors.
- Findings provide a foundation for advancing Hsp90-targeted cancer therapies.
More Related Videos
06:51Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
09:39Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology
Published on: March 31, 2022